BASAL CELL NAEVUS SYNDROME

This adverse event was reported 23 times

These drugs are most commonly taken by patients reporting BASAL CELL NAEVUS SYNDROME:

# Drug Count
0 ETOPOSIDE 8
1 CARBOPLATIN 7
2 IFOSFAMIDE 7
3 IFOSFAMIDE FOR INJECTION 7
4 DACTINOMYCIN 6
5 ADALIMUMAB 5
6 ADALIMUMAB-AATY 4
7 ADALIMUMAB-ADAZ 4
8 ADALIMUMAB-FKJP 4
9 VISMODEGIB 3
See all common drugs associated with BASAL CELL NAEVUS SYNDROME

BASAL CELL NAEVUS SYNDROME is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 DACTINOMYCIN 6 0.0027
1 VISMODEGIB 3 0.0003
2 IFOSFAMIDE FOR INJECTION 7 0.0003
3 ETOPOSIDE 8 0.0001
4 THIOTEPA 1 0.0001
5 ADALIMUMAB-FKJP 4 0.0001
6 ADALIMUMAB-AATY 4 0.0001
7 MECLIZINE HCL 12.5 MG 1 0.0001
8 ADALIMUMAB-ADAZ 4 0.0001
9 CARBOPLATIN 7 0.0001
See all drugs enriched for association with BASAL CELL NAEVUS SYNDROME

BASAL CELL NAEVUS SYNDROME is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Actinomycin [EPC] 6 0.0027
1 Hedgehog Pathway Inhibitor [EPC] 3 0.0003
2 Topoisomerase Inhibitor [EPC] 8 0.0001
3 Platinum-based Drug [EPC] 8 0.0000
4 Alkylating Drug [EPC] 7 0.0000
5 Interleukin-23 Antagonist [EPC] 2 0.0000
6 Interleukin-12 Antagonist [EPC] 1 0.0000
7 Serotonin-3 Receptor Antagonist [EPC] 1 0.0000
8 Janus Kinase Inhibitor [EPC] 1 0.0000
9 Estrogen [EPC] 1 0.0000
See all drug classes enriched for association with BASAL CELL NAEVUS SYNDROME